Search Results

Showing results 1281 - 1290 for leonard

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. | Pathology & Laboratory Medicine

... of Publication 2012 Authors Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ...

https://pathology.weill.cornell.edu/research/publications/selective-cdk46-inhibition-tumor-responses-pd0332991-patients-mantle-cell

c1-c1WCMfall04

... interact with theniches where they’refound in the human body. ANDREW LEONARD, SCIENCE PHOTO LIBRARY...

https://news.weill.cornell.edu/sites/default/files/publications/fall-winter-2006.pdf

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. | Pathology & Laboratory Medicine

..., S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ...

https://pathology.weill.cornell.edu/research/publications/clarithromycin-biaxin-lenalidomide-low-dose-dexamethasone-bird-versus

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. | Pathology & Laboratory Medicine

..., Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M Journal Br J Haematol Volume 138...

https://pathology.weill.cornell.edu/research/publications/lenalidomide-induced-myelosuppression-associated-renal-dysfunction-adverse

Outcome of deferred initial therapy in mantle-cell lymphoma. | Pathology & Laboratory Medicine

..., Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP Journal...

https://pathology.weill.cornell.edu/research/publications/outcome-deferred-initial-therapy-mantle-cell-lymphoma

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. | Pathology & Laboratory Medicine

..., Inghirami G, Diliberto M, Chen-Kiang S, Leonard JP Journal Blood Volume 133 Issue 11 Pagination 1201-1204...

https://pathology.weill.cornell.edu/research/publications/phase-1-trial-ibrutinib-plus-palbociclib-previously-treated-mantle-cell

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. | Pathology & Laboratory Medicine

... P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S Journal Cell Cycle...

https://pathology.weill.cornell.edu/research/publications/induction-prolonged-early-g1-arrest-cdk4cdk6-inhibition-reprograms-lymphoma

Postibrutinib outcomes in patients with mantle cell lymphoma. | Pathology & Laboratory Medicine

... Article Year of Publication 2016 Authors Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner...

https://pathology.weill.cornell.edu/research/publications/postibrutinib-outcomes-patients-mantle-cell-lymphoma

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. | Pathology & Laboratory Medicine

... Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, Diliberto M, Chen-Kiang S, Leonard...

https://pathology.weill.cornell.edu/research/publications/phase-i-trial-palbociclib-plus-bortezomib-previously-treated-mantle-cell

A worrisome interventricular septum: more than meets the eye. | Pathology & Laboratory Medicine

... Year of Publication 2011 Authors Wilson SR, Leonard JP, Geyer JT, Osborne JR, Weinsaft JW Journal J Am...

https://pathology.weill.cornell.edu/research/publications/worrisome-interventricular-septum-more-meets-eye

Showing results 1281 - 1290 for leonard